XBIT (XBiotech) Tariff Resilience Score: 7/10 (As of Jul. 04, 2026)


XBIT XBiotech Inc XBIT
32 GF Score
Price $2.30
! 2 Warning Signs
View Full Analysis

What is XBiotech Tariff Resilience Score?

XBiotech XBIT 32 Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus rates XBIT with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,373 Biotechnology companies, XBiotech ranks better than 90.39% on this metric.

XBiotech has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

XBiotech has Moderate exposure due to international supply chain. Primarily domestic sales reduce vulnerability. Historical tariff impacts have been minimal. Biotech industry may have specific exemptions. Mitigation through alternative suppliers is possible.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes XBiotech might have Highly Resilient.

XBiotech  (NAS:XBIT) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

XBiotech Tariff Resilience Score Related Terms

XBIT vs ACRV, EXOZ, BYSI: Tariff Resilience Score Comparison

For the Biotechnology subindustry, XBiotech's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XBiotech Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where XBiotech's Tariff Resilience Score falls into.


XBIT
32GF Score
XBiotech Inc XBIT
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
XBiotech (XBIT) has a Tariff Resilience Score of 7 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, XBiotech ranks #132 out of 1373 companies in the Biotechnology industry, placing it in the top 9.6%.
Is XBiotech's Tariff Resilience Score too high?
XBiotech's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. XBiotech's value of 7 is 75% above this industry median. Based on the distribution chart, XBiotech ranks #132 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, XBiotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does XBiotech's Tariff Resilience Score compare to ACRV and EXOZ?
According to the Biotechnology industry distribution chart, XBiotech ranks #132 out of 1373 companies for Tariff Resilience Score. This places XBiotech in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. XBiotech's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XBiotech's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XBiotech's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
XBiotech (XBIT) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. XBiotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For XBiotech (XBIT), the current Tariff Resilience Score is 7 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XBiotech Business Description

Other Exchanges 4XB:Germany
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
32GF Score

Get the complete analysis for XBIT

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.30
Price